Production (Stage)
AnaptysBio, Inc.
ANAB
$20.44
-$0.30-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.89% | 11.24% | -12.07% | -18.12% | -19.44% |
| Total Depreciation and Amortization | 0.42% | 0.88% | 0.93% | 1.05% | 1.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 98.66% | 81.08% | 50.88% | 14.65% | -2.18% |
| Change in Net Operating Assets | -257.03% | -20,370.68% | -102.51% | -149.72% | -221.49% |
| Cash from Operations | 18.50% | -12.03% | -6.05% | -65.03% | -73.03% |
| Capital Expenditure | 44.46% | 55.64% | 46.58% | 14.92% | -37.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -67.35% | -34.22% | 48.03% | 168.32% | 3,163.97% |
| Cash from Investing | -67.47% | -34.10% | 48.60% | 170.33% | 3,595.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,871.31% | 3,979.37% | 1,686.94% | -72.89% | -75.53% |
| Repurchase of Common Stock | 60.88% | 99.09% | 100.00% | 100.00% | 66.76% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 166.89% | 326.60% | 20.38% | -40.12% | -180.03% |
| Cash from Financing | 417.05% | 314.27% | 280.74% | 265.64% | -2,027.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 209.97% | 346.48% | 612.48% | 200.33% | 43.12% |